Izalontamab (SI-B001) is a bispecific anti-EGFR/HER3 monoclonal antibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab can be used for the research of cancer.
Izalontamab (5-46 mg/kg; i.v., every 7 days once, 4 doses in total) shows different anti-tumor efficacy in different types of tumors[1].
References:
[1]. Xue J, et al. Prediction of Human Pharmacokinetics and Clinical Effective Dose of SI-B001, an EGFR/HER3 Bi-specific Monoclonal Antibody. J Pharm Sci. 2020 Oct;109(10):3172-3180.